Based on the phase III ASTRUM‐007 study, serplulimab plus chemotherapy is superior to placebo plus chemotherapy and has become a new option for the first‐line treatment of patients with PD‐L1 positive, locally advanced, or metastatic ESCC. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.